Patients under 25 years with relapsed or refractory B-cell acute lymphoblastic leukaemia will gain access to Novartis’ Kymriah (tisagenlecleucel) through the Cancer Drugs Fund following NICE’s recommendations in its final draft guidelines.
Meindert Boysen, director of the Centre for Health Technology Evaluation at NICE, said: “NICE’s recommendation of tisagenlecleucel marks a new generation of personalised medicine that has the potential to transform the care of patients with cancer worldwide. CART-cell therapy is expensive and complex. We have worked in partnership with our stakeholders, NHS England and the company to make the therapy available to patients quickly.”
“Patients under 25 years with relapsed or refractory B-cell acute lymphoblastic leukaemia will gain access to Novartis’ Kymriah (tisagenlecleucel) through the Cancer Drugs Fund.“
Dr Alasdair Rankin, director of Research at Bloodwise, said: “CART-cell therapy can give children with leukaemia the real possibility of long-term survival if they do not respond to standard treatments. We hope that people will be able to access the therapy as soon as possible.”
A Novartis representative said: “This result is only possible due to our close collaboration with NHS England and NICE. In parallel with these discussions, we have been working alongside the selected specialist hospitals to ensure they are now trained and ready to deliver this life-saving therapy to eligible patients. We continue to work closely with NICE and the NHS to provide tisagenlecleucel access to adult patients with diffuse large B cell lymphoma (DLBCL) – the most common non-Hodgkin’s lymphoma, where there is also a high unmet need for patients who have relapsed and have no other treatment options. “